← Back to Search

Cohort A: Maintenance Therapy for Multiple Myeloma

Phase 2
Waitlist Available
Led By Taiga Nishihori, M.D.
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing a new way of giving a drug to see if it can help prevent relapse for people with multiple myeloma.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Relative Dose Intensity (RDI) Per Cohort
Secondary outcome measures
Complete Response Rate
Overall Survival (OS)
Progression Free Survival (PFS)

Trial Design

2Treatment groups
Active Control
Group I: Cohort A: Maintenance TherapyActive Control1 Intervention
Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.
Group II: Cohort B: Maintenance TherapyActive Control1 Intervention
Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
543 Previous Clinical Trials
135,465 Total Patients Enrolled
29 Trials studying Multiple Myeloma
2,083 Patients Enrolled for Multiple Myeloma
Novartis PharmaceuticalsIndustry Sponsor
2,859 Previous Clinical Trials
4,198,328 Total Patients Enrolled
38 Trials studying Multiple Myeloma
2,472 Patients Enrolled for Multiple Myeloma
Taiga Nishihori, M.D.Principal InvestigatorH. Lee Moffitt Cancer Center and Research Institute
1 Previous Clinical Trials
22 Total Patients Enrolled
1 Trials studying Multiple Myeloma
22 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
2016. "Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02722941.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top